Sentence examples for in conjunction with safety from inspiring English sources

From a point of view to utilize fracture mechanics of concrete for the solution of engineering problems, the problems in crack modeling, computational algorithm, and damping implementation are discussed in conjunction with safety assessment of concrete dam against large earthquakes.

CEAP is less widely utilised in conjunction with safety and efficacy analysis at the Federal level[ 33].

If an interaction is observed, clinical relevance should be evaluated in conjunction with safety and efficacy data and should be the primary consideration in data interpretation.

Governments in most OECD countries (as well as those mentioned above) utilise forms of CEAP in conjunction with safety and efficacy evaluations[ 23].

Vehicle occupant trauma to the eyes and associated facial structures has evolved rapidly in conjunction with safety-oriented vehicle design, including restraint systems.

A screenshot of the feature shared by Saksith Saiyasombut, a local journalist, shows that Facebook promoted a 26 December article by BangkokInformer.com in conjunction with the safety check.

BMW's move is not a recall in the strictest sense, a term generally reserved for a compulsory measure required by the National Highway Traffic Safety Administration, often in conjunction with serious safety issues.

This research examined the intervention effects of a simple one-hour training session designed to raise the awareness of noise as a workplace hazard in conjunction with general safety perceptions and attitudes in the workplace.

While COTS processors benefit from a large user base and the resulting maturity of the design process, customized processors provide the following advantages: (i design in conjunction with the safety argument, (ii design for good worst-case performance, (iii)using only features that can be easily analyzed, (iv the processor can be treated as a white box during verification and testing.

Indeed, these marginal benefits need to be considered in conjunction with the safety profiles and costs of denosumab and zoledronic acid when choosing an antiresorptive therapy for patients with metastatic bone disease from advanced cancer.

As new clinical trials are coming down the drug discovery pipeline, it is clear that the field is moving in a direction that values the development of molecular biomarkers, less subjective quantitative measures of symptom improvement, and rating scales developed specifically for use in FXS in conjunction with drug safety.